Survey on centralization of research ethics review for multicenter clinical trials in Japan

Akihiro Inano, Eiji Uchida, Yusuke Inoue, Hideo Kusuoka, Shimon Tashiro, Junichi Hasegawa, Noriko Morishita, Toshiyuki Sasaguri

研究成果: ジャーナルへの寄稿評論記事

抄録

We conducted a survey on centralization of research ethics review for multicenter clinical trials under the Pharmaceuticals and Medical Devises Law and calculated thedeinstitutionalization (referred to review not conducted by local IRB)rate for each type of clinical trial. We confirmed a trend of increase in overall deinstitutionalization rate from FY2008 to FY2013. The rate was 64.5% for phase III clinical trials in FY2013. However, the rate was extremely low in oncology trials, and was only 6.5%. Using our summarized data, we estimated that the resource spent on initial reviews for multicenter clinical trials amounted to 2 billion yen in 5 years. In the whole clinical trial arena, we need to consider carefully the balance between safeguarding research ethics and ensuring efficiency of the resource spent for this purpose.

元の言語英語
ページ(範囲)159-167
ページ数9
ジャーナルJapanese Journal of Clinical Pharmacology and Therapeutics
49
発行部数4
DOI
出版物ステータス出版済み - 1 1 2018

Fingerprint

Research Ethics
Multicenter Studies
Japan
Clinical Trials
Deinstitutionalization
Phase III Clinical Trials
Research Ethics Committees
Surveys and Questionnaires
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

これを引用

Survey on centralization of research ethics review for multicenter clinical trials in Japan. / Inano, Akihiro; Uchida, Eiji; Inoue, Yusuke; Kusuoka, Hideo; Tashiro, Shimon; Hasegawa, Junichi; Morishita, Noriko; Sasaguri, Toshiyuki.

:: Japanese Journal of Clinical Pharmacology and Therapeutics, 巻 49, 番号 4, 01.01.2018, p. 159-167.

研究成果: ジャーナルへの寄稿評論記事

Inano, Akihiro ; Uchida, Eiji ; Inoue, Yusuke ; Kusuoka, Hideo ; Tashiro, Shimon ; Hasegawa, Junichi ; Morishita, Noriko ; Sasaguri, Toshiyuki. / Survey on centralization of research ethics review for multicenter clinical trials in Japan. :: Japanese Journal of Clinical Pharmacology and Therapeutics. 2018 ; 巻 49, 番号 4. pp. 159-167.
@article{5eba40d8a14740919640a9bbe24a3f40,
title = "Survey on centralization of research ethics review for multicenter clinical trials in Japan",
abstract = "We conducted a survey on centralization of research ethics review for multicenter clinical trials under the Pharmaceuticals and Medical Devises Law and calculated thedeinstitutionalization (referred to review not conducted by local IRB)rate for each type of clinical trial. We confirmed a trend of increase in overall deinstitutionalization rate from FY2008 to FY2013. The rate was 64.5% for phase III clinical trials in FY2013. However, the rate was extremely low in oncology trials, and was only 6.5%. Using our summarized data, we estimated that the resource spent on initial reviews for multicenter clinical trials amounted to 2 billion yen in 5 years. In the whole clinical trial arena, we need to consider carefully the balance between safeguarding research ethics and ensuring efficiency of the resource spent for this purpose.",
author = "Akihiro Inano and Eiji Uchida and Yusuke Inoue and Hideo Kusuoka and Shimon Tashiro and Junichi Hasegawa and Noriko Morishita and Toshiyuki Sasaguri",
year = "2018",
month = "1",
day = "1",
doi = "10.3999/jscpt.49.159",
language = "English",
volume = "49",
pages = "159--167",
journal = "Japanese Journal of Clinical Pharmacology and Therapeutics",
issn = "0388-1601",
publisher = "Japanese Society of Clinical Pharmacology and Therapeutics",
number = "4",

}

TY - JOUR

T1 - Survey on centralization of research ethics review for multicenter clinical trials in Japan

AU - Inano, Akihiro

AU - Uchida, Eiji

AU - Inoue, Yusuke

AU - Kusuoka, Hideo

AU - Tashiro, Shimon

AU - Hasegawa, Junichi

AU - Morishita, Noriko

AU - Sasaguri, Toshiyuki

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We conducted a survey on centralization of research ethics review for multicenter clinical trials under the Pharmaceuticals and Medical Devises Law and calculated thedeinstitutionalization (referred to review not conducted by local IRB)rate for each type of clinical trial. We confirmed a trend of increase in overall deinstitutionalization rate from FY2008 to FY2013. The rate was 64.5% for phase III clinical trials in FY2013. However, the rate was extremely low in oncology trials, and was only 6.5%. Using our summarized data, we estimated that the resource spent on initial reviews for multicenter clinical trials amounted to 2 billion yen in 5 years. In the whole clinical trial arena, we need to consider carefully the balance between safeguarding research ethics and ensuring efficiency of the resource spent for this purpose.

AB - We conducted a survey on centralization of research ethics review for multicenter clinical trials under the Pharmaceuticals and Medical Devises Law and calculated thedeinstitutionalization (referred to review not conducted by local IRB)rate for each type of clinical trial. We confirmed a trend of increase in overall deinstitutionalization rate from FY2008 to FY2013. The rate was 64.5% for phase III clinical trials in FY2013. However, the rate was extremely low in oncology trials, and was only 6.5%. Using our summarized data, we estimated that the resource spent on initial reviews for multicenter clinical trials amounted to 2 billion yen in 5 years. In the whole clinical trial arena, we need to consider carefully the balance between safeguarding research ethics and ensuring efficiency of the resource spent for this purpose.

UR - http://www.scopus.com/inward/record.url?scp=85052578757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052578757&partnerID=8YFLogxK

U2 - 10.3999/jscpt.49.159

DO - 10.3999/jscpt.49.159

M3 - Review article

VL - 49

SP - 159

EP - 167

JO - Japanese Journal of Clinical Pharmacology and Therapeutics

JF - Japanese Journal of Clinical Pharmacology and Therapeutics

SN - 0388-1601

IS - 4

ER -